– USA, MA – Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) announced today that Thomas G. Auchincloss, Jr. will join its Board of Directors and serve as the independent chair of the Board’s Audit Committee, effective immediately. Mr. Auchincloss replaces Helmut Schühsler as Chair of the Audit Committee. Dr. Schühsler will remain a member of Concert’s Board of Directors.
“I would also like to thank Helmut for serving as Chair of our Audit Committee over the past year. We look forward to his continued service and leadership on the Board.”
Mr. Auchincloss is a financial expert and seasoned corporate financial executive. He has more than thirty years of financial experience including more than twenty years biotechnology experience in executive level financial, operational and advisory roles. Mr. Auchincloss is the former Chief Financial Officer of Metabolix, Inc., an industrial biotechnology company, where he oversaw finance, accounting, and corporate development. Before joining Metabolix, he held a variety of positions at Vertex Pharmaceuticals, Inc. most recently as Vice President, Finance and Treasurer. Mr. Auchincloss is presently Managing Partner of Counterpoint Trading Company LLC. He also serves as a trustee and Treasurer of Kieve Wavus Education, Inc. and as an advisor to Capital Formation Group, Inc. and Acelium. Mr. Auchincloss received a B.S. in Business Administration from Babson College and an M.B.A. in Finance from the Wharton School.
“Tom is an accomplished financial executive with a strong management record and I believe his deep financial expertise in public companies makes him a great addition to our board,” said Roger Tung, Ph.D., President and Chief Executive Officer of Concert Pharmaceuticals. “I would also like to thank Helmut for serving as Chair of our Audit Committee over the past year. We look forward to his continued service and leadership on the Board.”
About Concert
Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel small molecule drugs. This approach starts with approved drugs, advanced clinical candidates or previously studied compounds that have the potential to be improved with deuterium substitution to enhance clinical safety, tolerability or efficacy. The company is developing a broad pipeline targeting CNS disorders, renal disease, inflammation and cancer.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.